Alcantara Lyonna F, Warren Brandon L, Parise Eric M, Iñiguez Sergio D, Bolaños-Guzmán Carlos A
Department of Psychology and Program in Neuroscience, Florida State University, 1107 West Call Street, Tallahassee, FL, 32306, USA.
Psychopharmacology (Berl). 2014 Apr;231(8):1479-92. doi: 10.1007/s00213-014-3434-4. Epub 2014 Jan 23.
A common treatment strategy for pediatric attention deficit/hyperactivity disorder (ADHD) and major depressive disorder (MDD) is combined methylphenidate (MPH) and fluoxetine (FLX). This has raised concerns because MPH + FLX treatment may have pharmacodynamic properties similar to cocaine, potentially increasing drug abuse liability.
To examine the short- and long-term consequences of repeated vehicle, MPH, FLX, MPH + FLX, and cocaine treatment on gene expression in juvenile (postnatal days [PD] 20-34) and adult (PD 70-84) male mice. We further assessed whether juvenile drug treatment influenced subsequent sensitivity for nicotine in adulthood.
Juvenile and adult C57BL/6J mice received vehicle, MPH, FLX, MPH + FLX, or cocaine twice-daily for 15 consecutive days. Mice were sacrificed 24 h or 2 months after the last drug injection to assess drug-induced effects on the extracellular signal-regulated protein kinase-1/2 (ERK) pathway within the ventral tegmental area. Subsequent sensitivity for nicotine (0.05, 0.07, and 0.09 mg/kg) was measured using the place-conditioning paradigm (CPP) 24 h and 2 months after juvenile drug exposure.
MPH + FLX, or cocaine exposure in juvenile mice increased mRNA expression of ERK2 and its downstream targets (CREB, cFos, and Zif268), and increased protein phosphorylation of ERK2 and CREB 2 months after drug exposure. Similar mRNA findings were observed in the adult-treated mice. Findings on gene expression 24 h following drug treatment were variable. Juvenile drug exposure increased preference for nicotine when tested in adulthood.
Early-life MPH + FLX, or cocaine exposure similarly disrupts the ERK pathway, a signaling cascade implicated in motivation and mood regulation, and increases sensitivity for nicotine in adulthood.
治疗小儿注意力缺陷多动障碍(ADHD)和重度抑郁症(MDD)的一种常见策略是联合使用哌甲酯(MPH)和氟西汀(FLX)。这引发了人们的担忧,因为MPH+FLX治疗可能具有与可卡因相似的药效学特性,从而可能增加药物滥用的可能性。
研究反复给予溶媒、MPH、FLX、MPH+FLX和可卡因对幼年(出生后第[PD]20 - 34天)和成年(PD 70 - 84天)雄性小鼠基因表达的短期和长期影响。我们还评估了幼年药物治疗是否会影响成年后对尼古丁的后续敏感性。
幼年和成年C57BL/6J小鼠连续15天每天接受两次溶媒、MPH、FLX、MPH+FLX或可卡因治疗。在最后一次药物注射后24小时或2个月处死小鼠,以评估药物对腹侧被盖区内细胞外信号调节蛋白激酶-1/2(ERK)通路的诱导作用。在幼年药物暴露后24小时和2个月,使用条件性位置偏爱范式(CPP)测量对尼古丁(0.05、0.07和0.09mg/kg)的后续敏感性。
幼年小鼠暴露于MPH+FLX或可卡因会增加ERK2及其下游靶点(CREB、cFos和Zif268)的mRNA表达,并在药物暴露2个月后增加ERK2和CREB的蛋白磷酸化。在成年接受治疗的小鼠中也观察到了类似的mRNA结果。药物治疗后24小时的基因表达结果各不相同。幼年药物暴露在成年期测试时会增加对尼古丁的偏爱。
生命早期暴露于MPH+FLX或可卡因会同样破坏ERK通路,这是一种与动机和情绪调节有关的信号级联反应,并会增加成年后对尼古丁的敏感性。